Cargando…

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy

PURPOSE: To describe the effect of tocilizumab in two patients with thyroid associated orbitopathy (TAO). OBSERVATIONS: We present two patients with TAO who could not tolerate corticosteroids and had a reduction in clinical and laboratory markers of inflammatory activity with subsequent tocilizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, David J., Wagner, Lilly H., Seiff, Stuart R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722155/ https://www.ncbi.nlm.nih.gov/pubmed/29260102 http://dx.doi.org/10.1016/j.ajoc.2017.07.001

Ejemplares similares

A case of Tocilizumab-induced thrombocytopenia in steroid-resistant Graves orbitopathy
por: Cuculescu, Victoria, et al.
Publicado: (2023)

Long‐term outcomes in corticosteroid‐refractory Graves' orbitopathy treated with tocilizumab
por: Moi, Laura, et al.
Publicado: (2021)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
por: Şimşek, Tülay, et al.
Publicado: (2017)

Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience
por: Pérez-Moreiras, José V., et al.
Publicado: (2021)

Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents
por: Sharp, Michelle, et al.
Publicado: (2019)

Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
por: Wagner, Lilly H., et al.
Publicado: (2022)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Isolated primary amyloidosis of the inferior rectus muscle mimicking Graves’ orbitopathy
por: Monteiro, Mário Luiz Ribeiro, et al.
Publicado: (2016)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients
por: Sánchez-Bilbao, Lara, et al.
Publicado: (2020)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
por: Boutzios, Georgios, et al.
Publicado: (2023)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
por: Supronik, Jakub, et al.
Publicado: (2022)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Dermis-Fat Graft for Correction of Recurrent Severe Upper Eyelid Retraction in Graves’ Orbitopathy
por: Kuzmanović Elabjer, Biljana, et al.
Publicado: (2018)

Severe Graves' disease‐associated orbitopathy: A rare case of frontal bone hemangioma
por: Alamri, Ahmad, et al.
Publicado: (2020)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5331bfl7ba4sngbouhcls4lqa